MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.760
+0.320
+9.30%
After Hours: 3.750 -0.01 -0.27% 17:54 01/15 EST
OPEN
3.460
PREV CLOSE
3.440
HIGH
4.120
LOW
3.340
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
6.20
52 WEEK LOW
0.8120
MARKET CAP
14.23M
P/E (TTM)
-1.9861
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nano Dimension (NNDM), Triterras (TRIT), MicroVision (MVIS) and Bridgetown Holdings (BTWN) among premarket gainers
SIFCO Industries (SIF) +54% on Q4 results.Creative Realities (CREX) +21%.Triterras (TRIT) +19%.AIM ImmunoTech (AIM) +17%.Bridgetown Holdings Limited (BTWN) +16%.Lightbridge Corporation (LTBR) +24% after nabbing patent in Eurasia for nuclear fuel assemblies.IZEA Worldwide
Seekingalpha · 12/24/2020 13:21
NeuroMetrix Shares Up 6%; Co Granted U.S. Patent Titled 'Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode arrangement'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&f=G&l=50&d=PTXT&S1=(20201215.PD.+AND+neurometrix)&OS=ISD/12/15/2020+AND+n
Benzinga · 12/15/2020 14:54
STMicroelectronics, FireEye leads premarket losers' pack
Atossa Therapeutics (ATOS) -42% on announcing pricing of $20M underwritten public offering.Pluristem Therapeutics (PSTI) -42% after DMC recommendation following interim analysis of its Phase III CLI study.Photronics PLAB -18% on Q4 earnings release.Talos Energy
Seekingalpha · 12/09/2020 13:40
IBIO, SFIX, ARCT and LXRX among midday movers
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%.Contura Energy (CTRA)
Seekingalpha · 12/08/2020 17:40
Curis, Lexicon Pharmaceuticals leads healthcare gainers; Obalon Therapeutics, Arcturus Therapeutics among major losers
Gainers: Curis CRIS +333%, Lexicon Pharmaceuticals LXRX +78%, NeuroMetrix (NURO) +73%,  Cancer Genetics, Inc. (CGIX) +25%, Cantel Medical CMD +17%.Losers: Obalon Therapeutics (OBLN) -19%, Arcturus Therapeutics Holdings ARCT -16%, Agios Pharmaceuticals, Inc. (AGIO) -15%, iBio IBIO -15%, Trillium Therapeutics TRIL -14%.
Seekingalpha · 12/08/2020 16:00
Mid-Morning Market Update: Markets Edge Lower; AutoZone Earnings Top Estimates
Following the market opening Tuesday, the Dow traded down 0.10% to 30,040.36 while the NASDAQ fell 0.24% to 12,490.14. The S&P also fell, dropping 0.16% to 3,686.22.
Benzinga · 12/08/2020 15:12
SFIX, AR among premarket gainers
Curis (CRIS) +199% on encouraging CA-4948 data in leukemia.NeuroMetrix (NURO) +84%.Stitch Fix (SFIX) +39% on Q1 results.Lexicon Pharmaceuticals (LXRX) +31%.Cancer Genetics (CGIX) +28%.Smartsheet (SMAR) +18% on Q3 results.Tarena (TEDU) +18% on founder's going private
Seekingalpha · 12/08/2020 13:23
NeuroMetrix Reports Q3 2020 Financial Results
GlobeNewswire · 10/22/2020 12:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NURO. Analyze the recent business situations of NeuroMetrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 813.30K
% Owned: 21.49%
Shares Outstanding: 3.78M
TypeInstitutionsShares
Increased
2
14.26K
New
5
3.34K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.03%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Shai Gozani
Chief Financial Officer/Senior Vice President/Treasurer
Thomas Higgins
Senior Vice President
Francis McGillin
Independent Director
David Goodman
Independent Director
Nancy Katz
Independent Director
David Van Avermaete
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
03/14/2007
Dividend USD 0.15
03/28/2007
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NURO
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.